Research programme: liposomal therapeutics - Cytori

Drug Profile

Research programme: liposomal therapeutics - Cytori

Alternative Names: ATI-0721; ATI-1150; ATI-1186; ATI-1230; CRM 2100

Latest Information Update: 18 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Azaya Therapeutics
  • Developer Cytori Therapeutics
  • Class
  • Mechanism of Action DNA topoisomerase I inhibitors; Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Scleroderma
  • Discontinued Cancer

Most Recent Events

  • 15 Feb 2017 Preclinical trials in Scleroderma in USA (IV)
  • 15 Feb 2017 Azaya Therapeutics has been acquired and merged into Cytori Therapeutics
  • 02 Oct 2016 Discontinued - Preclinical for Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top